Comparative in vitro metabolism of indinavir in primates - A unique stereoselective hydroxylation in monkey

Xenobiotica

Volumn 30, Issue 2, 2000, Pages 117-129

  Chiba, M ^a   Nishime, J A ^a   Neway, W ^a   Lin, Y ^a   Lin, J H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 3A4; DEBRISOQUINE 4 HYDROXYLASE; INDAN DERIVATIVE; INDINAVIR; KETOCONAZOLE; MONOCLONAL ANTIBODY; QUINIDINE; QUININE;

ARTICLE; CHIMPANZEE; COMPARATIVE STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; LIVER MICROSOME; MONKEY; NONHUMAN; RHESUS MONKEY; SPECIES DIFFERENCE; STEREOCHEMISTRY; XENOBIOTIC METABOLISM;

CINCHONA PUBESCENS; HUMAN IMMUNODEFICIENCY VIRUS; MACACA FASCICULARIS; MACACA MULATTA; PAN TROGLODYTES; PRIMATES;

EID: 0034001402     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982500237721     Document Type: Article

References (29)

1. Balani, S. K., Arison, B. H., Mathai, L., Kauffman, L., Miller, R. R., Sterns, R. A., Chen, I.-W. and Lin, J. H., 1995, Metabolites of L-735,524, a potent IIIV-1 protease inhibitor, in human urine. Drug Metabolism and Disposition, 23, 266-270.
2. Chauret, N., Gauthier, A., Martin, J. and Nicoll-Griffith, D. A., 1997, In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metabolism and Disposition, 25, 1130-1136.
3. Chiba, M., Hensleigh, M. and Lin, J. H., 1997, Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Biochemical Pharmacology, 53, 1187-1195.
4. Chiba, M., Hensleigh, M., Nishime, J. A., Balani, S. and Lin, J. H., 1996, Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metabolism and Disposition, 24, 307-314.
5. Duignan, D. B., Sipes, I. G., Ciaccio, P. J. and Halpert, J. R., 1988, The metabolism of xenobiotics and endogenous compounds by the constitutive dog liver cytochrome P450 PBD-2. Archives of Biochemistry and Biophysics, 267, 294-304.
6. Eberhart, D. C., Gemzik, B., Halvorson, M. R. and Parkinson, A., 1991, Species differences in the toxicity and cytochrome P450 IIIA-dependent metabolism of digitoxin. Molecular Pharmacology, 40, 859-867.
7. Igarashi, T., Sakuma, T., Isogai, M., Nagata, R. and Kamataki, T., 1997, Marmoset liver cytochrome P450s: Study for expression and molecular cloning of their cDNAs. Archives of Biochemistry and Biophysics, 339, 85-91.
8. Jacqz-Aigrain, E., Gueguen, M., Zanger, U. M., Robieux, I. and Alvarez, F., 1991, Cytochrome P450IID subfamily in non-human primates. Catalytical and immunological characterization. Biochemical Pharmacology, 41, 1657-1663.
9. Kaminsky, L. S., 1989, Warfarin as a probe of cytochrome P450 function. Drug Metabolism Reviews, 20, 479-487.
10. Laddison, K. J., Speirs, A., Mankowski, D. C., Tweedie, D. and Lawton, M. P., 1995, Cloning, sequencing, and expression of the cynomolgus monkey liver cytochrome P450 that is orthologous to human CYP2D6. ISSX Proceedings, 8, 367.
11. Lin, J. H., 1995, Species similarities and differences in pharmacokinetics. Drug Metabolism and Disposition, 23, 1008-1021.
12. Lin, J. H., Chiba, M., Balani, S. K., Chen, I.-W., Kwei, G. Y.-S., Vastag, K. J. and Nishime, J. A., 1996, Species differences in the pharmacokinetics and metabolism of indinavir, a potent HIV protease inhibitor. Drug Metabolism and Disposition, 24, 1111-1120.
13. Lowry, O. H., Rosenbrough, N. J., Farr, A. L. and Randal, R. J., 1951, Protein measurement with Folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
14. Niwa, T., Kaneko, H., Naritomi, Y., Togawa, A., Shiraga, T., Iwasaki, K., Tozuka, Z. and Hata, T., 1995, Species and sex differences of testosterone and nifedipine oxidation in liver microsomes of rat, dog and monkey. Xenobiotica, 25, 1041-1049.
15. Omura, T. and Sato, R., 1964, The carbon monoxide binding pigment of liver microsomes. Journal of Biological Chemistry, 239, 2370-2378.
16. Otton, S. V., Tyndale, R. F., Wu, D., Inaba, T., Kalow, W. and Sellers, E. M., 1992, Catalytic and immunologic similarities between monkey and human liver cytochrome P-450db1 (human cytochrome P-450 2D6). Drug Metabolism and Disposition, 20, 1-5.
17. Ring, B. J., Parli, C. J., George, M. C. and Wrighton, S. A., 1994, In vitro metabolism of zatosetron. Interspecies comparison and role of CYP3A. Drug Metabolism and Disposition, 22, 352-357.
18. Rodrigues, A. D., Kukulka, M. J., Ferrero, J. L. and Cashman, J. R., 1995, In vitro hepatic metabolism of ABT-418 in chimpanzee (Pan troglodytes). A unique pattern of microsomal flavin-containing monooxygenase-dependent stereoselective N'-oxidation. Drug Metabolism and Disposition, 23, 1143-1152.
19. Sharer, J. E., Shipley, L. A., Vandenbranden, M. R., Binkley, S. N. and Wrighton, S. A., 1995, Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metabolism and Disposition, 23, 1231-1241.
20. Shimada, T., Mimura, M., Inoue, K., Nakamura, S., Oda, H., Ohmori, S. and Yamazaki, H., 1997, Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkey, and human. Archives of Toxicology, 71, 401-408.
21. Shou, M., Korzekwa, K. R., Krausz, K. W., Crespi, C. L., Gonzalez, F. J. and Gelboin, H. V., 1994, Regio- and stereo-selective metabolism of phenanthrene by twelve cDNA-expressed human, rodent and rabbit cytochromes P-450. Cancer Letters, 83, 305-313.
22. Smith, D. A., 1991, Species differences in metabolism and pharmacokinetics: are we close to an understanding? Drug Metabolism Reviews, 23, 355-373.
23. Smith, G., Modi, S., Pillai, I., Lian, L.-Y., Sutcliffe, M. J., Pritchard, M. P., Friedberg, T., Roberts, G. C. K. and Wolf, C. R., 1998, Determinants of the substrate specificity of human cytochrome P-450 CYP2D6: design and construction of a mutant with testosterone hydroxyase activity. Biochemical Journal, 331, 783-792.
24. Stevens, J. C., Shipley, L. A., Cashman, J. R., Vanderbranden, M. and Wrighton, S. A., 1993, Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities. Drug Metabolism and Disposition, 21, 753-760.
25. Vacca, J. P., Dorsey, B. D., Schleif, W. A., Levin, R. B., McDaniel, S. L., Darke, P. L., Zugay, J., Quintero, J. C., Blahy, O. M., Roth, E., Sardana, V., Schlabach, A. J., Graham, P. I., Condra, J. H., Gotlib, L., Holloway, M. K., Lin, J. H., Chen, I.-W., Vastag, K., Ostovic, D., Anderson, P. S., Emini, E. A. and Huff, J. R., 1994, L-735,524: An orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proceedings of the National Academy of Sciences, USA, 91, 4096-4100.
26. Wan, J., Imaoka, S., Chow, T., Hiroi, T., Yabusaki, Y. and Funae, Y., 1997, Expression of four rat CYP2D isoforms in Saccharomyces cerevisiae and their catalytic specificity. Archives of Biochemistry and Biophysics, 348, 383-390.
27. Wu, D., Otton, V., Morrow, P., Inaba, T., Kalow, W. and Sellers, E. M., 1993, Human hepatic cytochrome P450 2D6-like activity in nonhuman primates: catalytic characterization in vitro. Journal of Pharmacology and Experimental Therapeutics, 266, 715-719.
28. Yasumori, T., Chen, L., Nagata, K., Yamazoe, Y. and Kato, R., 1992, Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A). Journal of Pharmacology and Experimental Therapeutics, 264, 89-94.
29. Zhao, X. J. and Ishizaki, T., 1997, The in vitro hepatic metabolism of quinidine in mice, rats and dogs: comparison with human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 283, 1168-1176.